Marc Brockman, OD
Optometrist · West Palm Beach, FLNPI 1598764672
Payments from drug & device makers
Across 150 payments — averaging $43.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$453
- Bausch & Lomb Americas Inc.$400
- Aerie Pharmaceuticals, Inc.$385
- Johnson & Johnson Vision Care, Inc.$371
- Glaukos Corporation$345
- plus $3K from 22 others
What the payments were for
- Food & beverage$6,472100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $1,562 |
| Sun Pharmaceutical Industries Inc. | 14 | $453 |
| Bausch & Lomb Americas Inc. | 8 | $400 |
| Aerie Pharmaceuticals, Inc. | 10 | $385 |
| Johnson & Johnson Vision Care, Inc. | 4 | $371 |
| Glaukos Corporation | 4 | $345 |
| Tarsus Pharmaceuticals, Inc. | 7 | $289 |
| Eyevance Pharmaceuticals LLC | 2 | $284 |
| Sight Sciences, Inc. | 5 | $280 |
| Kala Pharmaceuticals, Inc. | 3 | $268 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $268 |
| Amgen(2 entities) | 3 | $249 |
| LKC Technologies, Inc. | 1 | $149 |
| Oyster Point Pharma, Inc. | 6 | $149 |
| Rayner Intraocular Lenses Limited | 1 | $125 |
| Alcon | 6 | $124 |
| Beaver-visitec International, Inc. | 1 | $122 |
| Novartis | 5 | $117 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $115 |
| Biotissue Holdings Inc. | 3 | $79 |
| Optos, Inc. | 1 | $62 |
| Mallinckrodt Hospital Products Inc. | 2 | $58 |
| Visionix USA, Inc | 1 | $56 |
| Harrow Eye, LLC | 2 | $45 |
| Shire North American Group Inc | 2 | $42 |
| Astellas Pharma US Inc | 1 | $29 |
| Thea Pharma Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$411
- LUMIGAN$373
- Flarex$284
- Acuvue$271
- MIEBO$268
- INVELTYS$246
- Rhopressa$233
- Rocklatan$233
- TEPEZZA$229
- DURYSTA$228
- iDose$159
- XIIDRA$143
- XDEMVY$126
- RESTASIS$125
- RayOne EMV$125
- RayOne Spheric$125
- RayOne Aspheric$125
- iStent Trabecular Micro-Bypass System Model iS3$123
- CEQUA$122
- OMNI(R) SURGICAL SYSTEM (US)$110
How this compares
$6,472 in reported general payments places this provider in the 90th percentile of 3,166 optometrist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 256 | $134,897 |
| RestasisCyclosporine | 129 | $113,988 |
| RocklatanNetarsudil Mesylat/Latanoprost | 70 | $45,823 |
| Latanoprost | 2,601 | $31,431 |
| XiidraLifitegrast | 31 | $23,939 |
| CombiganBrimonidine Tartrate/Timolol | 53 | $21,242 |
| RhopressaNetarsudil Mesylate | 36 | $20,820 |
| Alphagan PBrimonidine Tartrate | 31 | $15,298 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 794 | $13,967 |
| Timolol Maleate | 775 | $10,337 |
| Brimonidine Tartrate | 569 | $7,494 |
| VyzultaLatanoprostene Bunod | 19 | $7,166 |
| Travoprost | 44 | $6,773 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 37 | $6,733 |
| Dorzolamide Hcl | 258 | $4,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,562 | $285,425469 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $385 | $66,643106 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $400 | $31,10550 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,166 optometrist providers in Florida.
Other optometrist in West Palm Beach
- April JasperWest Palm Beach$781K
- Michael KynnJacksonville$4.5M
- Christine HalodaJacksonville$3.1M
- Bradley GieddWinter Park$2.5M
- Christopher PearsonLongwood$2.5M
- Mark PerryOrlando$1.6M
- Bryan StamJacksonville Beach$1M
- Oksana SovaJacksonville$841K
- James HoffmanOrange Park$795K
- Jerry RobbenSt Augustine$663K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.